These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 32231023)

  • 1. Dendritic Cells Pre-Pulsed with Wilms' Tumor 1 in Optimized Culture for Cancer Vaccination.
    Koya T; Date I; Kawaguchi H; Watanabe A; Sakamoto T; Togi M; Kato T; Yoshida K; Kojima S; Yanagisawa R; Koido S; Sugiyama H; Shimodaira S
    Pharmaceutics; 2020 Mar; 12(4):. PubMed ID: 32231023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma.
    Sakai K; Shimodaira S; Maejima S; Udagawa N; Sano K; Higuchi Y; Koya T; Ochiai T; Koide M; Uehara S; Nakamura M; Sugiyama H; Yonemitsu Y; Okamoto M; Hongo K
    J Neurosurg; 2015 Oct; 123(4):989-97. PubMed ID: 26252465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Immunotherapy for leukemia cells by using cytotoxic T lymphocyte specifically against WT1-derived peptide: an experimental study in vitro].
    Gu WY; Cao XS; Qiu GQ; Chen ZX; Sheng LX; Xie XB; He J; Cen JN; Shen HL
    Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(49):3475-80. PubMed ID: 16686063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dendritic Cell-Based Adjuvant Vaccination Targeting Wilms' Tumor 1 in Patients with Advanced Colorectal Cancer.
    Shimodaira S; Sano K; Hirabayashi K; Koya T; Higuchi Y; Mizuno Y; Yamaoka N; Yuzawa M; Kobayashi T; Ito K; Koizumi T
    Vaccines (Basel); 2015 Dec; 3(4):1004-18. PubMed ID: 26690485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design of an Optimized Wilms' Tumor 1 (WT1) mRNA Construct for Enhanced WT1 Expression and Improved Immunogenicity In Vitro and In Vivo.
    Benteyn D; Anguille S; Van Lint S; Heirman C; Van Nuffel AM; Corthals J; Ochsenreither S; Waelput W; Van Beneden K; Breckpot K; Van Tendeloo V; Thielemans K; Bonehill A
    Mol Ther Nucleic Acids; 2013 Nov; 2(11):e134. PubMed ID: 24253259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enzyme-Linked Immunosorbent Spot Assay for the Detection of Wilms' Tumor 1-Specific T Cells Induced by Dendritic Cell Vaccination.
    Higuchi Y; Koya T; Yuzawa M; Yamaoka N; Mizuno Y; Yoshizawa K; Hirabayashi K; Kobayashi T; Sano K; Shimodaira S
    Biomedicines; 2015 Dec; 3(4):304-315. PubMed ID: 28536414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of donor-derived Wilms tumor antigen 1-specific cytotoxic T lymphocytes with potent anti-leukemia activity for somatic cell therapy in children given haploidentical stem cell transplantation: a feasibility pre-clinical study.
    Ferulli F; Tanzi M; Turin I; Montini E; Rosti V; Acquafredda G; Lisini D; Compagno F; Boghen S; Licari A; Marseglia G; Zecca M; Montagna D
    Cytotherapy; 2019 Sep; 21(9):958-972. PubMed ID: 31279696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human CLEC9A antibodies deliver Wilms' tumor 1 (WT1) antigen to CD141
    Pearson FE; Tullett KM; Leal-Rojas IM; Haigh OL; Masterman KA; Walpole C; Bridgeman JS; McLaren JE; Ladell K; Miners K; Llewellyn-Lacey S; Price DA; Tunger A; Schmitz M; Miles JJ; Lahoud MH; Radford KJ
    Clin Transl Immunology; 2020; 9(6):e1141. PubMed ID: 32547743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Elimination of leukemic CD34+ progenitor cells by using cytotoxic T lymphocytes specifically targeting WT1-derived peptide: an experimental study in vitro].
    Gu WY; Chen ZX; Qiu GQ; Hu SY; Jia L; Wu W; He J; Cen JN; He B
    Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(48):3401-6. PubMed ID: 19159569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemoimmunotherapy targeting Wilms' tumor 1 (WT1)-specific cytotoxic T lymphocyte and helper T cell responses for patients with pancreatic cancer.
    Koido S; Homma S; Okamoto M; Takakura K; Gong J; Sugiyama H; Ohkusa T; Tajiri H
    Oncoimmunology; 2014 Nov; 3(10):e958950. PubMed ID: 25941581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decade-long WT1-specific CTLs induced by WT1 peptide vaccination.
    Suwabe T; Shibasaki Y; Tamura S; Katagiri T; Fuse K; Ida-Kurasaki T; Ushiki T; Sone H; Narita M; Masuko M
    Int J Hematol; 2024 Apr; 119(4):399-406. PubMed ID: 38427208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Immune effects of specific CTLs response induced by dendritic cells pulsed with NY-ESO-1 peptide].
    Liu JW; Lu X; Yang ZM; Deng LJ; Yang L
    Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Oct; 49(5):840-846. PubMed ID: 29045966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy.
    Goto T; Nishida T; Takagi E; Miyao K; Koyama D; Sakemura R; Hanajiri R; Watanabe K; Imahashi N; Terakura S; Murata M; Kiyoi H
    J Immunother; 2016 Oct; 39(8):306-15. PubMed ID: 27548033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessment of tumor vaccines.
    Schnurr M; Galambos P; Scholz C; Then F; Dauer M; Endres S; Eigler A
    Cancer Res; 2001 Sep; 61(17):6445-50. PubMed ID: 11522639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation of a cord blood-derived Wilms Tumor 1 dendritic cell vaccine for AML patients treated with allogeneic cord blood transplantation.
    de Haar C; Plantinga M; Blokland NJ; van Til NP; Flinsenberg TW; Van Tendeloo VF; Smits EL; Boon L; Spel L; Boes M; Boelens JJ; Nierkens S
    Oncoimmunology; 2015 Nov; 4(11):e1023973. PubMed ID: 26451309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality Verification with a Cluster-Controlled Manufacturing System to Generate Monocyte-Derived Dendritic Cells.
    Kawaguchi H; Sakamoto T; Koya T; Togi M; Date I; Watanabe A; Yoshida K; Kato T; Nakamura Y; Ishigaki Y; Shimodaira S
    Vaccines (Basel); 2021 May; 9(5):. PubMed ID: 34065520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Vivo Administration of Recombinant Human Granulocyte Colony-Stimulating Factor Increases the Immune Effectiveness of Dendritic Cell-Based Cancer Vaccination.
    Shimodaira S; Yanagisawa R; Koya T; Hirabayashi K; Higuchi Y; Sakamoto T; Togi M; Kato T; Kobayashi T; Koizumi T; Koido S; Sugiyama H
    Vaccines (Basel); 2019 Sep; 7(3):. PubMed ID: 31546936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential delivery of maturation stimuli increases human dendritic cell IL-12 production and enhances tumor antigen-specific immunogenicity.
    Kalady MF; Onaitis MW; Emani S; Abdel-Wahab Z; Tyler DS; Pruitt SK
    J Surg Res; 2004 Jan; 116(1):24-31. PubMed ID: 14732346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eliciting cytotoxic T lymphocytes against human laryngeal cancer-derived antigens: evaluation of dendritic cells pulsed with a heat-treated tumor lysate and other antigen-loading strategies for dendritic-cell-based vaccination.
    Wei FQ; Sun W; Wong TS; Gao W; Wen YH; Wei JW; Wei Y; Wen WP
    J Exp Clin Cancer Res; 2016 Jan; 35():18. PubMed ID: 26795730
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.